Pacific Biosciences of California Inc. buy UBS Group AG
Start price
17.11.23
/
50%
€7.17
Target price
17.11.24
€9.20
Performance (%)
-79.08%
End price
18.11.24
€1.50
Summary
This prediction ended on 18.11.24 with a price of €1.50. Massive losses of -79.08% were the result for the BUY prediction by UBS_Group_AG. UBS_Group_AG has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Pacific Biosciences of California Inc. | -12.692% | -12.692% | 27.685% |
| iShares Core DAX® | -1.553% | -0.123% | 12.654% |
| iShares Nasdaq 100 | -0.386% | -0.595% | 4.546% |
| iShares Nikkei 225® | 1.640% | 5.468% | 17.939% |
| iShares S&P 500 | 0.114% | -0.217% | 1.586% |
Comments by UBS_Group_AG for this prediction
In the thread Pacific Biosciences of California Inc. diskutieren
Pacific Biosciences of California, Inc. (NASDAQ: PACB) was upgraded by analysts at UBS Group AG from a "neutral" rating to a "buy" rating. They now have a $10.00 price target on the stock, down previously from $13.00.
Ratings data for PACB provided by MarketBeat
In the thread Trading Pacific Biosciences of California Inc.
Die von UBS_Group_AG gewählte maximale Laufzeit wurde überschritten
Stopped prediction by UBS_Group_AG for Pacific Biosciences of California Inc.
Pacific Biosciences of California Inc.
Start price
Target price
Perf. (%)
€5.53
16.02.24
16.02.24
€11.13
16.02.25
16.02.25
-67.79%
17.02.25
17.02.25
